作者
Sebastian E Sattui, Jean W Liew, Elizabeth R Graef, Ariella Coler-Reilly, Francis Berenbaum, Ali Duarte-Garcia, Carly Harrison, Maximilian F Konig, Peter Korsten, Michael S Putman, Philip C Robinson, Emily Sirotich, Manuel F Ugarte-Gil, Kate Webb, Kristen J Young, Alfred HJ Kim, Jeffrey A Sparks
发表日期
2020/7/2
来源
Expert Review of Clinical Immunology
卷号
16
期号
7
页码范围
659-666
出版商
Taylor & Francis
简介
Introduction
Several months into the COVID-19 pandemic, safe and effective treatments against this global health disaster have yet to be identified. Clinical research trials around the world are underway testing a wide array of possible medications. In particular, the off-label use of hydroxychloroquine for COVID-19 prophylaxis and treatment has created many unprecedented challenges for the scientific community and the public.
Areas covered
We critically assessed major events from February – May 2020 that contributed to widespread use of hydroxychloroquine for the treatment and prophylaxis of COVID-19. We aimed to explore how opinions toward hydroxychloroquine may shift from early enthusiasm (based on in vitro and preliminary clinical data) to the hope for a miracle cure (through communication and promotion of questionable results) and, finally, to a rise of skepticism as more in-depth analyses are …
学术搜索中的文章
SE Sattui, JW Liew, ER Graef, A Coler-Reilly… - Expert Review of Clinical Immunology, 2020